CN116459274A - Eucommia ulmoides extract composition, preparation method and application - Google Patents

Eucommia ulmoides extract composition, preparation method and application Download PDF

Info

Publication number
CN116459274A
CN116459274A CN202310512220.1A CN202310512220A CN116459274A CN 116459274 A CN116459274 A CN 116459274A CN 202310512220 A CN202310512220 A CN 202310512220A CN 116459274 A CN116459274 A CN 116459274A
Authority
CN
China
Prior art keywords
parts
preparation
eucommia
apigenin
rutin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202310512220.1A
Other languages
Chinese (zh)
Inventor
涂水才
肖卿
罗智勇
刘黎明
颜海英
刘胜
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
JIANGXI PUZHENG PHARMACEUTICAL CO Ltd
Original Assignee
JIANGXI PUZHENG PHARMACEUTICAL CO Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by JIANGXI PUZHENG PHARMACEUTICAL CO Ltd filed Critical JIANGXI PUZHENG PHARMACEUTICAL CO Ltd
Priority to CN202310512220.1A priority Critical patent/CN116459274A/en
Publication of CN116459274A publication Critical patent/CN116459274A/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/14—Preparation of compounds containing saccharide radicals produced by the action of a carbohydrase (EC 3.2.x), e.g. by alpha-amylase, e.g. by cellulase, hemicellulase
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The invention belongs to the field of medicines, and particularly relates to an eucommia ulmoides extract composition, a preparation method and application. The components of the composition in parts by weight are as follows: 5-10 parts of eucommia polysaccharide, 5-15 parts of rutin, 5-15 parts of hyperin, 1-5 parts of isochlorogenic acid C, 1-5 parts of apigenin and 1-5 parts of oleanolic acid. The preparation method comprises mixing eucommia polysaccharide, rutin, hyperoside, isochlorogenic acid C, apigenin and oleanolic acid or adding solvent and mixing. The preparation method is simple, is suitable for large-scale production and popularization and use, and reduces the cost.

Description

Eucommia ulmoides extract composition, preparation method and application
Technical Field
The invention belongs to the field of medicines, and particularly relates to an eucommia ulmoides extract composition, a preparation method and application.
Background
Membranous nephropathy (membranous nephropathy, MN), also known as membranous glomerulonephritis (membranous glomerulonephritis), is characterized pathologically by diffuse deposition of immune complexes under glomerular basement membrane epithelial cells with diffuse thickening of the basement membrane. Clinically, nephrotic Syndrome (NS) or asymptomatic proteinuria is the main manifestation.
Eucommia ulmoides is usually used as a Chinese medicinal material and is combined with other medicinal materials for treating diseases such as diabetic nephropathy.
The Chinese patent application 201810071132.1 discloses a Chinese medicinal composition for preventing and treating diabetic nephropathy and a preparation method thereof. The traditional Chinese medicine composition is mainly prepared from the following raw materials in parts by weight: 550-650 parts of astragalus membranaceus, 150-250 parts of radix puerariae, 150-250 parts of eucommia ulmoides, 150-250 parts of centella asiatica, 100-200 parts of periostracum cicadae, 100-200 parts of silkworm larva, 100-200 parts of burdock, 40-80 parts of rheum officinale and 100-200 parts of turmeric. The invention has precise and appropriate prescription, obvious curative effect, combined use of the medicines, pungent and bitter properties, and simultaneous application of the functions of invigorating kidney, removing blood stasis and opening the Xuanfu. Has better curative effect in reducing urine protein and improving kidney function, can improve general symptoms of diabetic nephropathy, protect kidney function, delay the progress of diabetic nephropathy, and is related to up-regulating the expression of podocyte related protein nephrin, podocin.
However, the use of the raw materials as a medicinal composition is very limited. Therefore, the application of eucommia ulmoides extracts and other traditional Chinese medicine extracts in foot cell injury and related diseases of membranous nephropathy is further researched, a new thought is provided for preventing and/or treating related diseases, the defects that side effects are difficult to determine and the substance action basis is complex and pharmacology is undefined due to various components in the conventional traditional Chinese medicine preparation can be further overcome, and the treatment effect is greatly improved.
Disclosure of Invention
In order to overcome the defects, the invention provides an eucommia ulmoides extract composition, a preparation method and application thereof in doxorubicin-induced human podocyte injury. The eucommia ulmoides extract composition has better effect of preventing and/or treating diseases related to human foot cell injury, so that a new thought is provided for preventing and/or treating diseases related to foot cell injury.
In one aspect, the invention provides an eucommia ulmoides extract composition comprising the following components: eucommia polysaccharide, rutin, hyperin, isochlorogenic acid C, apigenin and oleanolic acid.
Preferably, the composition comprises the following components in parts by weight: 5-10 parts of eucommia polysaccharide, 5-15 parts of rutin, 5-15 parts of hyperin, 1-5 parts of isochlorogenic acid C, 1-5 parts of apigenin and 1-5 parts of oleanolic acid.
Preferably, the composition comprises the following components in parts by weight: 5-8 parts of eucommia polysaccharide, 10-15 parts of rutin, 10-15 parts of hyperin, 3-5 parts of isochlorogenic acid C, 1-2 parts of apigenin and 3-5 parts of oleanolic acid.
Preferably, the composition comprises the following components in parts by weight: 5 parts of eucommia polysaccharide, 15 parts of rutin, 15 parts of hyperin, 3 parts of isochlorogenic acid, 1 part of apigenin and 3 parts of oleanolic acid.
Preferably, the preparation method of the eucommia ulmoides polysaccharide comprises the following steps:
(1) Adding solvent into cortex Eucommiae, and extracting to obtain extractive solution;
(2) Carrying out enzymolysis on the extracting solution to obtain an enzymolysis solution;
(3) And (3) precipitating the enzymolysis liquid with alcohol.
Preferably, the solvent is an aqueous solution containing 0.05-0.1% lecithin; the mass of the aqueous solution is 5-10 times of that of cortex eucommiae.
Preferably, the enzyme adopted by the enzymolysis comprises saccharifying enzyme, beta-glucanase and cellulase, and the addition amounts of the saccharifying enzyme, the beta-glucanase and the cellulase are respectively 0.1-0.5%, 0.05-0.1% and 0.1-0.5% of the mass of the extracting solution;
preferably, the alcohol precipitation adopts fractional precipitation, and specifically adopts 45-55% ethanol water solution, 80-90% ethanol water solution and 80-90% ethanol water solution containing 5-10% acetone in sequence.
It is still another object of the present invention to provide a method for preparing the above composition, comprising the steps of: mixing eucommia polysaccharide, rutin, hyperoside, isochlorogenic acid C, apigenin and oleanolic acid or adding solvent and mixing.
In still another aspect, the invention provides application of the eucommia ulmoides extract or the traditional Chinese medicine composition in preparation of medicines for preventing and/or treating diseases related to membranous nephropathy.
In particular, the podocyte injury related diseases include, but are not limited to, minimal disease kidney disease, localized segmental nephrosclerosis, membranous kidney disease, infection, wolf cancer nephritis, poisoning, and the like.
In still another aspect, the invention provides a pharmaceutical preparation for preventing and/or treating diseases related to membranous nephropathy, wherein the medicine comprises the eucommia ulmoides extract or the traditional Chinese medicine composition.
Specifically, the medicament also comprises a pharmaceutically acceptable carrier, wherein the carrier is any one or more of a slow release agent, an excipient, a filler, an adhesive, a wetting agent, a disintegrating agent, an absorption enhancer, an adsorption carrier, a surfactant or a lubricant.
Specifically, the medicine is any one of an external preparation, an oral preparation or an injection preparation.
Further specifically, the external preparation is a spray or an aerosol.
More specifically, the oral preparation is any one of granules, capsules, oral preparations, tablets, pills or vesicles.
Further specifically, the injection preparation adopts intradermal, subcutaneous, intramuscular, local or intravenous injection as a mode of administration.
Compared with the prior art, the invention has the following positive and beneficial effects:
(1) The eucommia ulmoides extract disclosed by the invention contains eucommia ulmoides polysaccharide, rutin, hyperin, isochlorogenic acid C, apigenin and oleanolic acid, and the components synergistically play a role in preventing and/or treating diseases related to membranous nephropathy.
(2) According to the invention, further researches show that the eucommia polysaccharide and hyperin are combined, and the eucommia polysaccharide and hyperin have remarkable synergistic effect on the treatment of membranous nephropathy, so that a new thought is provided for the prevention and/or treatment of membranous nephropathy related diseases.
(3) The preparation method of the traditional Chinese medicine composition is simple, is suitable for large-scale production, popularization and use, and reduces the cost.
Detailed Description
The present invention will be described in further detail with reference to the following examples, which are not intended to limit the present invention, but are merely illustrative of the present invention. The experimental methods used in the following examples are not specifically described, but the experimental methods in which specific conditions are not specified in the examples are generally carried out under conventional conditions, and the materials, reagents, etc. used in the following examples are commercially available unless otherwise specified.
Example 1
The eucommia ulmoides extract composition comprises the following components in parts by weight: 5 parts of eucommia polysaccharide, 15 parts of rutin, 15 parts of hyperin, 3 parts of isochlorogenic acid, 1 part of apigenin and 3 parts of oleanolic acid.
The preparation method of eucommia polysaccharide comprises the following steps:
(1) Adding 8 times of aqueous solution containing 0.08% lecithin into eucommia bark, and heating and refluxing to extract to obtain extractive solution;
(2) Adding 0.3% of saccharifying enzyme, 0.05% of beta-glucanase and 0.3% of cellulase into the extract, and performing enzymolysis for 1.5 hours at 50 ℃ and pH of 5.5 to obtain an enzymolysis solution;
(3) Boiling and inactivating the enzymolysis liquid for 5min at 100 ℃, sequentially adopting alcohol precipitation, namely alcohol precipitation of an aqueous solution of 50% alcohol, an aqueous solution of 85% alcohol and an aqueous solution of 85% alcohol containing 8% acetone, and drying to obtain the final product.
The preparation method of the eucommia ulmoides extract comprises the following steps:
mixing eucommia polysaccharide, rutin, hyperoside, isochlorogenic acid C, apigenin and oleanolic acid.
Example 2
The eucommia ulmoides extract composition comprises the following components in parts by weight: 5 parts of eucommia polysaccharide, 5 parts of rutin, 5 parts of hyperin, 1 part of isochlorogenic acid C, 1 part of apigenin and 1 part of oleanolic acid.
The preparation method of eucommia polysaccharide comprises the following steps:
(1) Adding 5 times of aqueous solution containing 0.05% lecithin into eucommia bark, and heating and refluxing to extract to obtain extract;
(2) Adding 0.1% of saccharifying enzyme, 0.1% of beta-glucanase and 0.1% of cellulase into the extract, and performing enzymolysis for 2 hours at 45 ℃ and pH6 to obtain an enzymolysis solution;
(3) Boiling the enzymolysis solution at 100deg.C for 5min, precipitating with 55% ethanol water solution, 90% ethanol water solution and 80% ethanol water solution containing 10% acetone, and drying.
The preparation method of the eucommia ulmoides extract composition comprises the following steps:
mixing eucommia polysaccharide, rutin, hyperoside, isochlorogenic acid C, apigenin and oleanolic acid.
Example 3
The eucommia ulmoides extract composition comprises the following components in parts by weight: 10 parts of eucommia polysaccharide, 15 parts of rutin, 15 parts of hyperin, 5 parts of isochlorogenic acid, 5 parts of apigenin and 5 parts of oleanolic acid.
The preparation method of eucommia polysaccharide comprises the following steps:
(1) Adding 10 times of aqueous solution containing 0.1% lecithin into eucommia bark, and heating and refluxing to extract to obtain extractive solution;
(2) Adding 0.5% of saccharifying enzyme, 0.05% of beta-glucanase and 0.5% of cellulase into the extract, and carrying out enzymolysis for 1h at 55 ℃ and pH5 to obtain an enzymolysis solution;
(3) Boiling the enzymolysis solution at 100deg.C for 5min, precipitating with 45% ethanol water solution, 80% ethanol water solution and 80% ethanol water solution containing 5% acetone, and drying.
The preparation method of the eucommia ulmoides extract composition comprises the following steps:
mixing eucommia polysaccharide, rutin, hyperoside, isochlorogenic acid C, apigenin and oleanolic acid.
Comparative example 1
The eucommia ulmoides extract composition comprises the following components in parts by weight: 20 parts of eucommia polysaccharide, 15 parts of rutin, 3 parts of isochlorogenic acid C, 1 part of apigenin and 3 parts of oleanolic acid.
The preparation method of eucommia polysaccharide comprises the following steps:
(1) Adding 8 times of aqueous solution containing 0.08% lecithin into eucommia bark, and heating and refluxing to extract to obtain extractive solution;
(2) Adding 0.3% of saccharifying enzyme, 0.05% of beta-glucanase and 0.3% of cellulase into the extract, and performing enzymolysis for 1.5 hours at 50 ℃ and pH of 5.5 to obtain an enzymolysis solution;
(3) Boiling the enzymolysis solution at 100deg.C for 5min, precipitating with 50% ethanol water solution, 85% ethanol water solution and 85% ethanol water solution containing 8% acetone, and drying.
The preparation method of the eucommia ulmoides extract composition comprises the following steps:
mixing eucommia polysaccharide, rutin, isochlorogenic acid C, apigenin and oleanolic acid uniformly.
Comparative example 2
The eucommia ulmoides extract composition comprises the following components in parts by weight: 15 parts of rutin, 20 parts of hyperin, 3 parts of isochlorogenic acid C, 1 part of apigenin and 3 parts of oleanolic acid.
The preparation method of the eucommia ulmoides extract composition comprises the following steps:
mixing rutin, hyperoside, isochlorogenic acid C, apigenin and oleanolic acid.
Comparative example 3
The eucommia ulmoides extract composition comprises the following components in parts by weight: 5 parts of eucommia polysaccharide, 15 parts of rutin, 15 parts of hyperin, 3 parts of isochlorogenic acid, 1 part of apigenin and 3 parts of oleanolic acid.
The preparation method of eucommia polysaccharide comprises the following steps:
(1) Adding 8 times of aqueous solution containing 0.08% lecithin into eucommia bark, and heating and refluxing to extract to obtain extractive solution;
(2) Adding 0.35% of saccharifying enzyme and 0.3% of cellulase by weight into the extract, and performing enzymolysis at 50 ℃ and pH of 5.5 for 1.5 hours to obtain enzymolysis solution;
(3) Boiling the enzymolysis solution at 100deg.C for 5min, precipitating with 50% ethanol water solution, 85% ethanol water solution and 85% ethanol water solution containing 8% acetone, and drying.
The preparation method of the eucommia ulmoides extract composition comprises the following steps:
mixing eucommia polysaccharide, rutin, hyperoside, isochlorogenic acid C, apigenin and oleanolic acid.
Comparative example 4
The eucommia ulmoides extract composition comprises the following components in parts by weight: 5 parts of eucommia polysaccharide, 15 parts of rutin, 15 parts of hyperin, 3 parts of isochlorogenic acid, 1 part of apigenin and 3 parts of oleanolic acid.
The preparation method of eucommia polysaccharide comprises the following steps:
(1) Adding 8 times of aqueous solution containing 0.08% lecithin into eucommia bark, and heating and refluxing to extract to obtain extractive solution;
(2) Adding 0.3% of saccharifying enzyme, 0.05% of beta-glucanase and 0.3% of cellulase into the extract, and performing enzymolysis for 1.5 hours at 50 ℃ and pH of 5.5 to obtain an enzymolysis solution;
(3) Boiling the enzymolysis solution at 100deg.C for 5min, sequentially adding ethanol until the ethanol concentration in the solution system is 85%, precipitating with ethanol, standing, and drying.
The preparation method of the eucommia ulmoides extract composition comprises the following steps:
mixing eucommia polysaccharide, rutin, hyperoside, isochlorogenic acid C, apigenin and oleanolic acid.
Experiment one, pharmacodynamic study of the composition of the present invention on membranous nephropathy
1.1 preparation of experimental reagents:
the PBS buffer composition is shown in Table 1 below.
TABLE 1
Preparing a preimmune liquid: adding a small amount of PBS solution into 0.08g of C-BSA, grinding, adding PBS to 40ml, mixing, adding 40ml of Freund's incomplete adjuvant, and grinding.
C-BSA solution preparation: adding a small amount of PBS solution into 1.6-g C-BSA, grinding, adding PBS solution until the final concentration of C-BSA is 2.5mg/ml, and mixing.
1.2 preparation of animal models
1mg of C-BSA was taken and added to 0.5ml of PBS, and the mixture was mixed with an equal amount of Freund's incomplete adjuvant to prepare a milky suspension, and the suspension was subcutaneously injected in the groin at multiple sites on the bilateral axilla of the rat. After 1 week of pre-immunization, each rat was injected with 2.5mg of C-BSA intravenously at 3 times per week for 3 weeks. Then, the 24h urine protein is quantitatively measured, the 24h urine protein exceeds 10mg, and the molding is successful.
1.3 grouping and administration
Model rats were divided into model groups, low, medium, and high dose groups of example 1, comparative examples 1, 2, 3, and 4 groups of 10 animals each; another 10 normal rats were taken as blank;
example 1 eucommia ulmoides extract compositions prepared in the corresponding groups of rats in the low, medium and high dose groups and in the comparative examples 1, 2, 3 and 4 groups were respectively administered by intragastric administration at a dose of 5g/kg once a day;
the model group perfuses the stomach with a considerable volume of physiological saline;
the stomach was irrigated continuously for 4 weeks.
1.4 experimental results and statistical analysis
The urine and plasma albumin levels were measured at 24 hours after 4 weeks in each group of rats and the results are shown in tables 2-3.
TABLE 2
Group of N Urine protein/mg/24 h
Blank group 10 9.04±0.83
Model group 10 54.33±7.26 *
Example 1 Low dose group 10 17.41±5.58 #
Dose group in example 1 10 15.80±3.75 #
Example 1 high dose group 10 11.27±5.32 #
Comparative example 1 group 10 28.09±7.61 #&
Comparative example 2 group 10 33.48±6.94 #&
Comparative example 3 group 10 24.57±6.59 #&
Comparative example 4 group 10 26.04±4.37 #&
Note that: the model set is compared to the normal set, * p is less than 0.05; in comparison with the set of models, # p is less than 0.05; in comparison with the low dose group of example 1, & P＜0.05。
TABLE 3 Table 3
Group of N Plasma albumin/g/L
Blank group 10 35.78±9.29
Model group 10 31.02±4.16 *
Example 1 Low dose group 10 36.11±5.42 #
Dose group in example 1 10 36.94±7.80 #
Example 1 high dose group 10 38.14±8.37 #
Comparative example 1 group 10 31.05±5.31 &
Comparative example 2 group 10 33.29±6.33 #&
Comparative example 3 group 10 34.20±3.57 #&
Comparative example 4 group 10 33.18±4.35 #&
Note that: comparing the model group with the normal group, wherein P is less than 0.05; in comparison with the set of models, # p is less than 0.05; in comparison with the low dose group of example 1, & P＜0.05。
the foregoing examples illustrate only a few embodiments of the invention and are described in detail herein without thereby limiting the scope of the invention. It should be noted that it will be apparent to those skilled in the art that several variations and modifications can be made without departing from the spirit of the invention, which are all within the scope of the invention. Accordingly, the scope of protection of the present invention is to be determined by the appended claims.

Claims (10)

1. An eucommia ulmoides extract composition is characterized by comprising the following components: eucommia polysaccharide, rutin, hyperin, isochlorogenic acid C, apigenin and oleanolic acid.
2. The composition according to claim 1, characterized by comprising the following components in parts by weight: 5-10 parts of eucommia polysaccharide, 5-15 parts of rutin, 5-15 parts of hyperin, 1-5 parts of isochlorogenic acid C, 1-5 parts of apigenin and 1-5 parts of oleanolic acid.
3. The composition according to claim 1, characterized by comprising the following components in parts by weight: 5-8 parts of eucommia polysaccharide, 10-15 parts of rutin, 10-15 parts of hyperin, 3-5 parts of isochlorogenic acid C, 1-2 parts of apigenin and 3-5 parts of oleanolic acid.
4. The composition according to claim 1, characterized by comprising the following components in parts by weight: 5 parts of eucommia polysaccharide, 15 parts of rutin, 15 parts of hyperin, 3 parts of isochlorogenic acid, 1 part of apigenin and 3 parts of oleanolic acid.
5. The composition according to claim 1, wherein the preparation method of eucommia ulmoides polysaccharide comprises the following steps:
(1) Adding solvent into cortex Eucommiae, and extracting to obtain extractive solution;
(2) Carrying out enzymolysis on the extracting solution to obtain an enzymolysis solution;
(3) And (3) precipitating the enzymolysis liquid with alcohol.
6. The composition according to claim 5, wherein the solvent is an aqueous solution containing lecithin at a mass concentration of 0.05 to 0.1%; the mass of the aqueous solution is 5-10 times of that of cortex eucommiae.
7. The composition according to claim 5, wherein the enzymes used for the enzymolysis comprise saccharifying enzyme, beta-glucanase and cellulase, and the addition amounts of the saccharifying enzyme, the beta-glucanase and the cellulase are respectively 0.1-0.5%, 0.05-0.1% and 0.1-0.5% of the mass of the extracting solution; the alcohol precipitation adopts fractional precipitation, and specifically adopts 45-55% ethanol water solution, 80-90% ethanol water solution and 80-90% ethanol water solution containing 5-10% acetone in sequence.
8. A process for the preparation of a composition as claimed in any one of claims 1 to 7, comprising the steps of: mixing eucommia polysaccharide, rutin, hyperoside, isochlorogenic acid C, apigenin and oleanolic acid or adding solvent and mixing.
9. Use of the eucommia ulmoides extract composition of any one of claims 1 to 7 in the preparation of a medicament for preventing and/or treating diseases related to membranous nephropathy.
10. A pharmaceutical preparation for preventing and/or treating diseases related to membranous nephropathy, characterized in that: the pharmaceutical preparation comprises the eucommia ulmoides extract composition of any one of claims 1 to 8; the medicine also comprises a pharmaceutically acceptable carrier, wherein the carrier is any one or more of a slow release agent, an excipient, a filler, an adhesive, a wetting agent, a disintegrating agent, an absorption promoter, an adsorption carrier, a surfactant or a lubricant; the medicine is any one of an external preparation, an oral preparation or an injection preparation.
CN202310512220.1A 2023-05-09 2023-05-09 Eucommia ulmoides extract composition, preparation method and application Pending CN116459274A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310512220.1A CN116459274A (en) 2023-05-09 2023-05-09 Eucommia ulmoides extract composition, preparation method and application

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202310512220.1A CN116459274A (en) 2023-05-09 2023-05-09 Eucommia ulmoides extract composition, preparation method and application

Publications (1)

Publication Number Publication Date
CN116459274A true CN116459274A (en) 2023-07-21

Family

ID=87175406

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202310512220.1A Pending CN116459274A (en) 2023-05-09 2023-05-09 Eucommia ulmoides extract composition, preparation method and application

Country Status (1)

Country Link
CN (1) CN116459274A (en)

Similar Documents

Publication Publication Date Title
CN103768152B (en) Flos Osmanthi Fragrantis phenethyl alcohol glycoside extract and its production and use
US20140087010A1 (en) Preparation method for extractive of jinxuan hemorrhoid washing powder botanicals
CN101293038A (en) Gallbladder leaves extract, preparing method, its preparation and uses
CN100500196C (en) Method for preparing paris polyphylla total saponin
CN1267113C (en) Extract of mulberry twig and its extracting process and novel usage
CN1723955A (en) Extractive of rhizome belamcandae, prepn. method and use thereof
CN1927293A (en) Chinese medicine composition for treating skin burn and scald
CN1397560A (en) Process for extracting general platycodoside and platycoligenin D from platycodon root, its medical application and its Chinese medicine
CN106822331A (en) To lock application of the lichee bark extract based on shape polymer polyphenol in treatment antihyperuricemic disease drug or health products are prepared
CN114224934B (en) Eucommia ulmoides extract for improving microcirculation
CN116459274A (en) Eucommia ulmoides extract composition, preparation method and application
CN114796280A (en) Compound paracetamol and chlorphenamine maleate granules and preparation process thereof
CN113797235A (en) Preparation method of compound ganoderma lucidum spore oil with liver protection effect
CN101380356B (en) Tibetan medicine Duyiwei total flavone extract and extraction method and use thereof
CN102145076B (en) The pharmaceutical applications of Radix Rehmanniae and extract thereof
CN100548308C (en) The pharmaceutical composition that is used for autoimmune disease and organ transplantation rejection
CN101375954B (en) Medicament composition, preparation method thereof and use
CN101181336A (en) Method for refining valid target of bitter gourd for dropping blood sugar
CN105079174B (en) A kind of tonic tablet for kidney-reinforcing and preparation method thereof
CN110101802A (en) A kind of pharmaceutical composition for treating hypertension
CN114404433B (en) Pinoresinol diglucoside composition for improving microcirculation and preparation method thereof
CN113880960B (en) Anti-hypoxia active dendrobium officinale polysaccharide and steam explosion preparation method and application thereof
CN108250258B (en) New flavone glycoside prepared by fermentation and ultrasonic extraction technology
CN104840747A (en) Traditional Chinese medicine composition capable of resisting thyroid cancer activity and preparation method and application thereof
CN106008216A (en) Pharmaceutical composition of didanosine and application of pharmaceutical composition in biological medicines

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination